Melissa Dercks
Adult Health · Green Bay, WINPI 1710202577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $826 and has fallen 90.3% since, to $80 in 2024.
Across 71 payments — averaging $31.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$511
- AbbVie$397
- Lundbeck LLC$229
- Livanova USA, Inc.$152
- Medtronic$135
- EMD Serono, Inc.$76
- plus $717 from 23 others
What the payments were for
- Food & beverage$2,17298%
- Education$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $511 |
| AbbVie(2 entities) | 17 | $397 |
| Lundbeck LLC | 4 | $229 |
| Livanova USA, Inc. | 2 | $152 |
| Medtronic | 3 | $135 |
| EMD Serono, Inc. | 2 | $76 |
| Merz Pharmaceuticals, LLC | 2 | $75 |
| Biogen | 3 | $63 |
| Neurelis, Inc. | 2 | $63 |
| Argenx US, Inc. | 2 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $48 |
| Genentech USA, Inc. | 2 | $41 |
| Boston Scientific | 1 | $39 |
| Neurocrine Biosciences, Inc. | 2 | $36 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Bristol Myers Squibb | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| GE HealthCare | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Banner Life Sciences, LLC | 1 | $22 |
| Piramal Critical Care | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $20 |
| UCB, Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Amgen | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| SK Life Science, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR$128
- VYEPTI$104
- KESIMPTA$101
- MAYZENT$101
How this compares
$2,217 in reported general payments places this provider in the 85th percentile of 170 adult health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 23 | $181,318 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 15 | $116,230 |
| Emgality PenGalcanezumab-Gnlm | 101 | $115,528 |
| QuliptaAtogepant | 86 | $114,404 |
| Nurtec OdtRimegepant Sulfate | 72 | $89,614 |
| Aimovig AutoinjectorErenumab-Aooe | 92 | $83,412 |
| UbrelvyUbrogepant | 73 | $67,442 |
| Dimethyl Fumarate | 12 | $64,007 |
| Dalfampridine ErDalfampridine | 108 | $52,339 |
| LamictalLamotrigine | 25 | $34,631 |
| BriviactBrivaracetam | 16 | $31,606 |
| NayzilamMidazolam | 33 | $22,056 |
| Glatiramer Acetate | 15 | $21,142 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 12 | $20,068 |
| FycompaPerampanel | 12 | $14,807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $397 | $181,847159 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $36 | $181,31823 claims |
| PfizerNurtec Odt | $18 | $89,61472 claims |
| UCB, Inc.Briviact, Nayzilam | $19 | $53,66249 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 170 adult health providers in Wisconsin.
Other adult health in Green Bay
- Heidi DowdGreen Bay$383
- Dawn SagrilloWhitefish Bay$247K
- Lindsey SimpsonMuskego$67K
- Winsome PantonMilwaukee$46K
- Anatoliy VelikodanovMilwaukee$10K
- Tatjana StevanovicWest Allis$10K
- Annike CollinsMilwaukee$9K
- Kristine TwomeyNeenah$5K
- Kay ConradtAppleton$4K
- Nicole RosinMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.